Benjamin L. Palleiko's most recent trade in KalVista Pharmaceuticals Inc was a trade of 479,989 Common Stock done . Disclosure was reported to the exchange on June 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 479,989 | 0 (0%) | 2% | 0 | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 304,688 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 255,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 125,001 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 113,920 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 92,560 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 85,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 75,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 71,700 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 52,600 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 47,354 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 37,500 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 33,800 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 33,750 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 29,611 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 23,250 | 255,750 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 23,250 | 490,915 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 26.78 per share. | 21 May 2026 | 10,926 | 479,989 (2%) | 0% | 26.8 | 292,646 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2026 | 2,419 | 468,794 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2026 | 2,419 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 26.76 per share. | 17 May 2026 | 1,129 | 467,665 (2%) | 0% | 26.8 | 30,212 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 7,120 | 469,697 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 7,120 | 92,560 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 26.71 per share. | 11 May 2026 | 3,322 | 466,375 (2%) | 0% | 26.7 | 88,731 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 20,312 | 472,127 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 20,312 | 304,688 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 16 Apr 2026 | 9,550 | 462,577 (2%) | 0% | 20.2 | 193,066 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2026 | 15,625 | 125,001 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2026 | 15,625 | 458,508 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 16.08 per share. | 06 Mar 2026 | 6,693 | 451,815 (2%) | 0% | 16.1 | 107,633 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 325,000 | 325,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2025 | 15,625 | 140,626 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2025 | 15,625 | 431,814 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 16.51 per share. | 06 Dec 2025 | 7,294 | 424,520 (2%) | 0% | 16.5 | 120,424 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 23,250 | 427,129 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 23,250 | 302,250 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 13.45 per share. | 21 Nov 2025 | 10,940 | 416,189 (2%) | 0% | 13.5 | 147,154 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 9,364 | 408,345 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 6,945 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 14.48 per share. | 17 Nov 2025 | 4,466 | 403,879 (2%) | 0% | 14.5 | 64,665 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 2,419 | 4,838 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 7,120 | 106,800 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 7,120 | 402,309 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.55 per share. | 11 Nov 2025 | 3,328 | 398,981 (2%) | 0% | 11.5 | 38,438 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2025 | 15,625 | 402,483 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2025 | 15,625 | 156,251 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 15.84 per share. | 06 Sep 2025 | 7,294 | 395,189 (2%) | 0% | 15.8 | 115,537 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 23,250 | 397,798 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 23,250 | 325,500 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 21 Aug 2025 | 10,940 | 386,858 (2%) | 0% | 13.2 | 144,657 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2025 | 9,362 | 378,957 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2025 | 6,944 | 6,945 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 17 Aug 2025 | 4,409 | 374,548 (2%) | 0% | 13.2 | 58,141 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2025 | 2,418 | 7,257 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 113,920 | 113,920 | - | - | Employee Stock Option | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 113,920 | 113,920 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2025 | 87,500 | 402,574 (2%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 15.69 per share. | 08 Jul 2025 | 32,979 | 369,595 (2%) | 0% | 15.7 | 517,523 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2025 | 15,625 | 171,876 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2025 | 15,625 | 322,243 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 14.50 per share. | 06 Jun 2025 | 7,169 | 315,074 (1%) | 0% | 14.5 | 103,951 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 23,250 | 348,750 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 23,250 | 316,617 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.88 per share. | 21 May 2025 | 9,999 | 306,618 (1%) | 0% | 11.9 | 118,743 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 9,364 | 297,175 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 6,945 | 13,889 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.84 per share. | 17 May 2025 | 3,808 | 293,367 (1%) | 0% | 11.8 | 45,097 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 2,419 | 9,675 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 15,625 | 294,480 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 15,625 | 187,501 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.97 per share. | 06 Mar 2025 | 6,669 | 287,811 (1%) | 0% | 12.0 | 79,828 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 372,000 | 372,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 9,363 | 283,959 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 6,944 | 20,834 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.82 per share. | 17 Feb 2025 | 5,104 | 278,855 (1%) | 0% | 9.8 | 50,143 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 2,419 | 12,094 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 15,625 | 282,223 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 15,625 | 203,126 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.75 per share. | 06 Dec 2024 | 7,627 | 274,596 (1%) | 0% | 9.7 | 74,363 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 30,198 | 280,998 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 20,834 | 0 | - | - | Performance Stock Units | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.26 per share. | 17 Nov 2024 | 14,400 | 266,598 (1%) | 0% | 9.3 | 133,294 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 6,945 | 27,778 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 2,419 | 14,513 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 15,625 | 258,152 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 15,625 | 218,751 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 12.19 per share. | 06 Sep 2024 | 7,352 | 250,800 (1%) | 0% | 12.2 | 89,622 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 30,195 | 256,742 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 20,833 | 20,834 | - | - | Performance Stock Units | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 17 Aug 2024 | 14,215 | 242,527 (1%) | 0% | 12.0 | 170,769 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 6,944 | 34,723 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 2,418 | 16,932 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 15,625 | 234,375 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 15,625 | 232,012 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.53 per share. | 06 Jun 2024 | 7,465 | 224,547 (1%) | 0% | 11.5 | 86,068 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 51,031 | 238,346 (1%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.76 per share. | 17 May 2024 | 21,959 | 216,387 (1%) | 0% | 11.8 | 258,337 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 20,834 | 0 | - | - | Performance Stock Units |